418 related articles for article (PubMed ID: 19029469)
1. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
McKenney JM; Davidson MH; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
[TBL] [Abstract][Full Text] [Related]
3. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.
Blasi E; Bamberger M; Knight D; Engwall M; Wolk R; Winter S; Betts A; John-Baptiste A; Keiser J
J Cardiovasc Pharmacol; 2009 Jun; 53(6):507-16. PubMed ID: 19455053
[TBL] [Abstract][Full Text] [Related]
4. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
de Haan W; de Vries-van der Weij J; van der Hoorn JW; Gautier T; van der Hoogt CC; Westerterp M; Romijn JA; Jukema JW; Havekes LM; Princen HM; Rensen PC
Circulation; 2008 May; 117(19):2515-22. PubMed ID: 18458167
[TBL] [Abstract][Full Text] [Related]
5. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?
Schaefer EJ; Asztalos BF
Curr Opin Cardiol; 2007 Jul; 22(4):373-8. PubMed ID: 17556892
[TBL] [Abstract][Full Text] [Related]
6. HDL metabolism and CETP inhibition.
Barkowski RS; Frishman WH
Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
[TBL] [Abstract][Full Text] [Related]
7. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
[TBL] [Abstract][Full Text] [Related]
8. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
Schaefer EJ; Asztalos BF
Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
[TBL] [Abstract][Full Text] [Related]
9. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).
Nicholls SJ; Tuzcu EM; Brennan DM; Tardif JC; Nissen SE
Circulation; 2008 Dec; 118(24):2506-14. PubMed ID: 19029466
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
Davidson MH; McKenney JM; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1774-81. PubMed ID: 17084249
[TBL] [Abstract][Full Text] [Related]
11. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
[TBL] [Abstract][Full Text] [Related]
12. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Barter P
Am J Cardiol; 2009 Nov; 104(10 Suppl):10E-5E. PubMed ID: 19895939
[TBL] [Abstract][Full Text] [Related]
13. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
Shinkai H
Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
[TBL] [Abstract][Full Text] [Related]
14. Effect of torcetrapib on the progression of coronary atherosclerosis.
Nissen SE; Tardif JC; Nicholls SJ; Revkin JH; Shear CL; Duggan WT; Ruzyllo W; Bachinsky WB; Lasala GP; Tuzcu EM;
N Engl J Med; 2007 Mar; 356(13):1304-16. PubMed ID: 17387129
[TBL] [Abstract][Full Text] [Related]
15. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
[TBL] [Abstract][Full Text] [Related]
16. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
Vergeer M; Stroes ES
Am J Cardiol; 2009 Nov; 104(10 Suppl):32E-8E. PubMed ID: 19895942
[TBL] [Abstract][Full Text] [Related]
17. [Torcetrapib increases mortality in patients with a high risk of cardiovascular disorders].
Rensen PC; Jukema JW
Ned Tijdschr Geneeskd; 2008 May; 152(19):1088-90. PubMed ID: 18552062
[TBL] [Abstract][Full Text] [Related]
18. Effects of torcetrapib in patients at high risk for coronary events.
Barter PJ; Caulfield M; Eriksson M; Grundy SM; Kastelein JJ; Komajda M; Lopez-Sendon J; Mosca L; Tardif JC; Waters DD; Shear CL; Revkin JH; Buhr KA; Fisher MR; Tall AR; Brewer B;
N Engl J Med; 2007 Nov; 357(21):2109-22. PubMed ID: 17984165
[TBL] [Abstract][Full Text] [Related]
19. Torcetrapib + atorvastatin (Pfizer).
Burnett JR
Curr Opin Investig Drugs; 2005 Sep; 6(9):944-50. PubMed ID: 16187694
[TBL] [Abstract][Full Text] [Related]
20. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.
Bots ML; Visseren FL; Evans GW; Riley WA; Revkin JH; Tegeler CH; Shear CL; Duggan WT; Vicari RM; Grobbee DE; Kastelein JJ;
Lancet; 2007 Jul; 370(9582):153-160. PubMed ID: 17630038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]